Kibria & Sons Pharmaceuticals Private Limited
About Kibria & Sons Pharmaceuticals Private Limited
Data last updated:
Kibria & Sons Pharmaceuticals Private Limited is a private limited company based in Kanpur, Uttar Pradesh, India. It operates in the diversified business activities segment of the business services sector. It was incorporated on 14 September 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Kanpur, under CIN U74995UP2017PTC096975. Its GSTIN is 09AAGCK7668F1Z2 (Uttar Pradesh).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors including Sheeba Hashmi and Faran Hashmi.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 117/K/13 Flat No. 809 Anand Tower Sarvodaya Nagar Hansnagar, Kanpur, Uttar Pradesh, India – 208005.
As per the financials filed for FY 2025, the company reported a revenue of ₹46.12 Lakh, a growth of 9% compared to the previous year. For the same year it recorded a net profit of ₹6.4 Lakh (net margin 13.9%) and EBITDA of ₹9.47 Lakh (EBITDA margin 20.5%). Revenue has grown at a compounded annual rate (CAGR) of 4% over three years and 5% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Kibria & Sons Pharmaceuticals Private Limited's registered office is in Kanpur, Uttar Pradesh. Its e-mail address is in the company report.
- Email
- Registered Address117/K/13 Flat No. 809 Anand Tower Sarvodaya Nagar Hansnagar, Kanpur, Uttar Pradesh, India – 208005
- IndustryBusiness Services, Miscellaneous Business Activities, Other Services, Services Rendered By Liaison Offices
To see the full contact details of Kibria & Sons Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Kibria & Sons Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Kibria & Sons Pharmaceuticals Private Limited, buy the company report.
Financials of Kibria & Sons Pharmaceuticals Private Limited
FY 2025 filings availableKibria & Sons Pharmaceuticals Private Limited reported revenue of ₹46.12 Lakh (up 9% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 5% over five years, including 9% growth in the latest year. EBITDA rose 42% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹9.47 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹6.4 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 20.5% | ||||
| Net Profit Margin | 13.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Kibria & Sons Pharmaceuticals Private Limited, buy the company report.
Board of directors of Kibria & Sons Pharmaceuticals Private Limited
Kibria & Sons Pharmaceuticals has 3 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sheeba Hashmi | Director | 14 Sep 2017 | 9 Years 1 Months | Current |
| Faran Hashmi | Director | 14 Sep 2017 | 9 Years 1 Months | Current |
| Shiban Kibria | Director | 14 Sep 2017 | 9 Years 1 Months | Current |
Peer comparison
Kibria & Sons Pharmaceuticals Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Limbos Pharmaceuticals Private Limited | ₹46.31 Lakh (FY 2025) | 17.0% | Punjab, India | |||
| Kibria & Sons Pharmaceuticals Private Limitedthis company | ₹46.12 Lakh (FY 2025) | ₹6.4 Lakh | 13.9% | 9.0% | Kanpur, Uttar Pradesh, India | |
| Shiva Audax Pharmaceuticals Private Limited | ₹46.06 Lakh (FY 2024) | 0.0% | Patna, Bihar, India | |||
| Semicon Pharmaceuticals Private Limited | ₹45.55 Lakh (FY 2024) | 648.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Kibria & Sons Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Kibria & Sons Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Kibria & Sons Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Kibria & Sons Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAGCK7668F1Z2 | Uttar Pradesh | Active | 20 Feb 2018 |
To see the full GST registrations and return filing status of Kibria & Sons Pharmaceuticals Private Limited, buy the company report.
Recent activity
Kibria & Sons Pharmaceuticals Private Limited has 3 board changes on record since 2017: 3 appointments. The latest: Faran Hashmi was appointed as Director on 14 Sep 2017.
Frequently asked questions
Kibria & Sons Pharmaceuticals is an active private limited company based in Kanpur, Uttar Pradesh, India. The company works in miscellaneous business activities, within the business services industry. It was incorporated on 14 September 2017 (9+ years old) and is registered under CIN U74995UP2017PTC096975.
Kibria & Sons Pharmaceuticals has 3 current directors:
- Sheeba Hashmi - Director
- Faran Hashmi - Director
- Shiban Kibria - Director
The latest financial statements of Kibria & Sons Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.
The GSTIN of Kibria & Sons Pharmaceuticals is 09AAGCK7668F1Z2, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Kibria & Sons Pharmaceuticals is U74995UP2017PTC096975. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Kibria & Sons Pharmaceuticals was incorporated on 14 September 2017, making it 9+ years old. It is registered with the Registrar of Companies, Kanpur.
The peers of Kibria & Sons Pharmaceuticals by revenue are Limbos Pharmaceuticals Private Limited, Shiva Audax Pharmaceuticals Private Limited, Semicon Pharmaceuticals Private Limited, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Faran Hashmi was appointed as Director on 14 Sep 2017. Sheeba Hashmi was appointed as Director on 14 Sep 2017. Shiban Kibria was appointed as Director on 14 Sep 2017.
The registered office of Kibria & Sons Pharmaceuticals is at 117K13 Flat No. 809 Anand Tower Sarvodaya Nagar Hansnagar, Kanpur, Uttar Pradesh, India – 208005.
Kibria & Sons Pharmaceuticals operates in the business services industry, in the miscellaneous business activities segment.
The compliance status of Kibria & Sons Pharmaceuticals is compliant as of 14 August 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
